MedTrace Logo

Fructose Consumption and Metabolic Dysregulation

NCT01445730 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2021-06-15

Study results available
· View outcomes & findings →

Summary

High fructose intake is increasingly recognized as causative in development of prediabetes, metabolic syndrome and cardiovascular disease (CVD). The mechanisms underlying fructose-induced metabolic disturbances are unclear but are beginning to be unraveled. In contrast to metabolism of glucose, the breakdown of fructose leads to the generation of metabolites that stimulate hepatic de novo lipogenesis (DNL) and increased levels of both fasting and postprandial triglycerides. The key lipogenic transcription factor seems to be activated by fructose independently of insulin. However, it is still controversial whether fructose consumption increases DNL in man to the extent that it induces metabolic disturbances. Animal studies have shown that also the adipose tissue is responsive to fructose feeding fructose, and that high fructose-feeding induces insulin resistance and inflammation in the adipose tissue. The role of intestinal insulin resistance in fructose-induced dysmetabolism has not been studied in detail. The critical question is whether the metabolic disturbances are induced by calorie excess or by fructose per se.

Conditions

  • Central Obesity
  • Hypertriglyceridemia

Interventions

DIETARY_SUPPLEMENT

Fructose

3 month fructose diet 75 g/day

Sponsors & Collaborators

  • Sahlgrenska University Hospital

    collaborator OTHER

  • Lund University

    collaborator OTHER

  • University of Naples

    collaborator OTHER

  • Laval University

    collaborator OTHER

  • Marja-Riitta Taskinen

    lead OTHER

Principal Investigators

  • Marja-Riitta Taskinen, Professor · Helsinki University Central Hospital, Biomedicum

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2015-05-31
Completion
2015-06-30

Countries

  • Canada
  • Finland
  • Italy
  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01445730 on ClinicalTrials.gov